Noxopharm Shares Surge as Lupus Drug Clears Key Safety Tests

2 min read | February 04, 2025 11:03 AM AEDT | By Team Kalkine Media

Google News:

Noxopharm Shares Surge as Lupus Drug Clears Key Safety Tests — Image source: Shutterstock

Recent News

Could ASX Growth Stocks Be Set for the Next Market Shift?

Woolworths Climbs While Coles Skirts 52-Week Lows: The Supermarket Spl...

Retail Under Pressure: Why ASX Retail Stocks Face a Tougher Road Ahead

ASX Growth Stocks: Hidden Catalysts and Market Signals

Make Kalkine Media
My Trusted Source

Highlights

Noxopharm shares jumped 11% to 10cps following positive test results.

SOF-SKN, a topical lupus treatment, passed first-stage in vitro safety tests.

Final preclinical study to be completed before human trials begin in 2025.

Biotech firm Noxopharm (ASX:NOX) saw its shares surge 11% to 10cps on Tuesday morning after announcing that its experimental lupus medication, SOF-SKN, had successfully cleared initial safety testing.

The company confirmed that its topical Sofra drug candidate passed in vitro safety tests, moving it a step closer to human trials scheduled for 2025.

Breakthrough for Autoimmune Treatment

Lupus is a chronic autoimmune disease that causes the body’s immune system to attack its own tissues, leading to organ and tissue damage. SOF-SKN, a topical gel, is designed to target TLR7 receptors, which are believed to play a role in triggering the condition.

According to Noxopharm’s latest test results, the drug has shown no genetic mutation risks or cardiac toxicity, a crucial milestone in early-stage drug development. Additionally, an ultraviolet (UV) light exposure test confirmed the gel’s stability, ensuring safe use even after exposure to sunlight.

A final preclinical study remains before SOF-SKN progresses to human trials.

Market Reaction and Future Outlook

Despite the initial 11% surge, Noxopharm shares later settled at 8.5cps. The stock’s movement reflects investor optimism about the drug’s commercial potential while awaiting further developments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.